Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Alexion Pharmaceuticals Inc

+ Add to Watchlist

ALXN:US

174.7500 USD 5.3300 2.96%

As of 20:10:00 ET on 04/27/2015.

Snapshot for Alexion Pharmaceuticals Inc (ALXN)

Open: 181.5700 Day's Range: 173.8800 - 182.3500 Volume: 1,479,997
Previous Close: 180.0800 52wk Range: 147.8100 - 203.3000 1-Yr Rtn: +14.07%

Stock Chart for ALXN

No chart data available.
  • ALXN:US 174.6000
  • 1D
  • 1M
  • 1Y
180.0800
Interactive ALXN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ALXN

Current P/E Ratio (ttm) 55.9693
Estimated P/E(12/2015) 29.9486
Relative P/E vs. SPX 3.0071
Earnings Per Share (USD) (ttm) 3.1223
Est. EPS (USD) (12/2015) 5.8350
Est. PEG Ratio 1.2794
Market Cap (M USD) 34,876.04
Shares Outstanding (M) 199.58
30 Day Average Volume 1,375,264
Price/Book (mrq) 9.9205
Price/Sale (ttm) 15.3000
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 07/24/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ALXN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ALXN

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops proprietary immunoregulatory compounds for the treatment of autoimmune and cardiovascular diseases. The Company develops C5 complement inhibitors and Apogens which are two classes of potential therapeutic compounds designed to selectively target specific disease-causing segments of the immune system.

David L HallalChief Executive OfficerVikas SinhaExec VP/CFO
Saqib IslamExec VP/Chief Strategy OfficerDominique MonnetExec VP/Chief Mktg Officer
More Company Profile & Key Executives for ALXN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil